StockData

Burning Rock Biotech vs Veracyte

BNR and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNR and VCYT compare

Veracyte grew revenue faster over the last twelve months (17.3% versus 4.6% for Burning Rock Biotech).

Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −10.3% at Burning Rock Biotech.

Veracyte scores higher on the StockData Score (16 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNRVCYT
Size and price
Market cap–$1.9B
Share price$12.50$24.23
Change, 1 year6.5%−38.4%
Change, 5 years−90.9%−41.7%
Beta (5Y)2.521.92
Employees667755
StockData Score
Total score416 (better)
Valuation score04 (better)
Growth score13 (better)
Performance score13 (better)
Health score26 (better)
Dividend score00
Valuation
P/E–17.3×
P/S–3.5×
P/B–1.4×
EV/EBITDA–13.0×
P/FCF–11.7×
FCF yield–8.5%
Fair value–$36.51
Margin of safety–33.6%
Growth
Revenue growth (TTM)4.6%17.3% (better)
Revenue growth, 5Y average4.6%34.5% (better)
Net income growth (TTM)–335%
EPS growth (TTM)–324%
Profitability
Gross margin74.7% (better)71.7%
Operating margin−10.2%18.8% (better)
Net margin−10.3%20.4% (better)
FCF margin−6.2%29.5% (better)
Return on equity−9.9%8.8% (better)
Return on invested capital−72.5%10.0% (better)
Financial health
Debt / equity0.00 (better)0.00
Current ratio2.999.16 (better)
Altman Z-score–12.65
Piotroski F-score57 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions1.8%111%
Held by insiders19.0%1.7%
Insider net buying, 12 months$11.6M (better)−$18.6M
Short interest, % of float–12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.